Clinical Trial to Evaluate the Efficacy and Safety of 'GLA5PR GLARS-NF1 Tab.' in Peripheral Neuropathic Pain

• Status: Completed
• Trial end date: 2019-01-08
• Target enrollment: 0
• Participant gender: All

Summary

A multi-center, randomized, double-blind, parallel, active-controlled phase III clinical trial to evaluate the efficacy and safety of 'GLA5PR GLARS-NF1 Tab.' and 'Pregabalin' in peripheral neuropathic pain

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daewon Pharmaceutical Co., Ltd.
• Treatments: Pregabalin

Criteria

Inclusion Criteria:

• both male and female who are over 19-year-old

• patient whose pain scale is 4~9

• patient who has pain of mononeuropathy

Exclusion Criteria:

• patient whose CCr is <60ml/min

• patient who has other pain which is not from mononeuropathy

• patient who is going to have an operation during this study

• patient who has abnormal ECG